Filing Flows › Comparisons › IBRX vs AUTL
ImmunityBio vs Autolus Therapeutics: IBRX and AUTL compared
ImmunityBio is the larger company: $51.2M of revenue in its latest quarter (Q2 2026) against $45.7M for Autolus Therapeutics (Q2 2026). Autolus Therapeutics is growing faster (+118% against +94% a year earlier). Autolus Therapeutics is more profitable, with an operating margin of -95.9% against -120.4%.
Where the money goes: IBRX and AUTL
ImmunityBio (IBRX) · Q2 2026
ImmunityBio, Q2 2026: revenue $51.2M (+94% year over year), operating margin -120.4%, net loss $230M, operating cash flow −$66.5M. The chart follows the revenue to costs, profit and cash.
Autolus Therapeutics (AUTL) · Q2 2026
Autolus Therapeutics, Q2 2026: revenue $45.7M (+118% year over year), operating margin -95.9%, net loss $39.1M, operating cash flow −$25.1M. The chart follows the revenue to costs, profit and cash.
| ImmunityBio (IBRX) | Autolus Therapeutics (AUTL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $51.2M | $45.7M |
| Revenue growth, Y/Y | +94% | +118% |
| Operating margin | -120.4% | -95.9% |
| Net earnings | −$230M | −$39.1M |
| Net margin | -449.6% | -85.6% |
| Operating cash flow | −$66.5M | −$25.1M |
Where the revenue comes from
ImmunityBio
- Product revenue, net: $50.7M (99%)
- Other revenues: $568K (1%)
Autolus Therapeutics
- Product revenue, net: $45.7M (100%)
- License revenue: $17K (0%)
Questions
Which is bigger, ImmunityBio or Autolus Therapeutics?
ImmunityBio is the larger company: $51.2M of revenue in its latest quarter (Q2 2026) against $45.7M for Autolus Therapeutics (Q2 2026).
Is ImmunityBio or Autolus Therapeutics growing faster?
Autolus Therapeutics is growing faster (+118% against +94% a year earlier).
Which is more profitable, ImmunityBio or Autolus Therapeutics?
Autolus Therapeutics is more profitable, with an operating margin of -95.9% against -120.4%.
More: ImmunityBio earnings · how ImmunityBio makes money · Autolus Therapeutics earnings · how Autolus Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 4, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.